GSK
China ban for corrupt pharma firms
January 2, 2014Medical Communications, Sales and Marketing Cameron, China, GSK, Witty, bribery, lilly
GSK changes sales tactics
December 17, 2013Medical Communications, Sales and Marketing GSK, Witty, bribery, corruption, cuts, sales, transparency
GlaxoSmithKline is to remove individual staff sales targets and end doctor payments for activities that promote its products. The UK …
GSK funnels another £200m into UK manufacturing
December 12, 2013Manufacturing and Production, Sales and Marketing GSK, Taylor, UK, manufacturing
GlaxoSmithKline has made good on a pledge to invest in UK-based production, with £200 million ($328m) earmarked for plant upgrades …
GSK launches cancer ‘consortium’
December 6, 2013Research and Development, Sales and Marketing Cancer, GSK, octc, oncology, research
GlaxoSmithKline has formed a consortium of cancer research organisations in North America and Europe in a bid to accelerate the …
Prime minister backs GSK in corruption row
December 4, 2013Medical Communications, Sales and Marketing China, GSK, bribery, david cameron
Prime minister David Cameron has defended London-based pharma giant GlaxoSmithKline over its treatment in China during a visit to the …
Witty goes to China
December 3, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing China, GSK, Witty, bribery
GlaxoSmithKline chief executive Sir Andrew Witty has embarked on a potentially delicate diplomatic mission as part of a UK trade …
GSK veteran named chief executive for Takeda
December 2, 2013Sales and Marketing GSK, Takeda, christophe weber
Asia’s biggest drugmaker Takeda has named GlaxoSmithKline’s Christophe Weber as the leading candidate for the role of its next chief …
GSK using ‘sledgehammer’ tactics on agencies
November 29, 2013Sales and Marketing Cameron, China, GSK, horlicks, sky
GlaxoSmithKline is being accused of using ‘sledgehammer’ tactics by marketing agencies promoting its products after the firm allegedly demanded cash …
FDA U-turn on Avandia
November 26, 2013Sales and Marketing Avandia, CDER, FDA, GSK, diabetes, nissen, type 2
The FDA has delivered a shock verdict that the stringent restrictions on GlaxoSmithKline’s diabetes medicine Avandia should be lifted, despite …
GSK expands Montrose API plant with £25m investment
November 25, 2013Manufacturing and Production GSK, Scotland, montrose
GlaxoSmithKline is planning to invest £25 million ($40m) at a facility in Scotland that will take on production of ingredients …
GSK makes £425 million Aspen sale
November 21, 2013Sales and Marketing GSK, Merck, South Africa, aspen
GlaxoSmithKline has raised £425 million with the sale of 28.2 million shares that it has in Africa’s biggest drugmaker as …
GSK heart disease drug fails late-stage trial
November 13, 2013Sales and Marketing GSK, darapladib, heart, statin
GSK has said its investigational chronic coronary heart disease pill darapladib has failed to meet its primary endpoint in a …
GSK ‘may not face corporate charges’
November 5, 2013Medical Communications, Sales and Marketing China, GSK, bribery
GlaxoSmithKline is unlikely to face a company-wide charge for corruption following investigations by authorities in China according to reports. The …
GSK: no Votrient Code breaches
November 4, 2013Medical Communications, Sales and Marketing GSK, PMCPA, Pfizer
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
